Medtronic reports positive data from AdaptivCRT algorithm study

17 May 2018 (Last Updated May 17th, 2018 12:03)

Medtronic has reported positive results from a real-world study of the effects of its AdaptivCRT algorithm on patients suffering from heart failure.

Medtronic reports positive data from AdaptivCRT algorithm study
Medtronic’s cardiac resynchronisation therapy-pacemaker, Viva CRT-P. Credit: Medtronic.

Medtronic has reported positive results from a real-world study of the effects of its AdaptivCRT algorithm on patients suffering from heart failure.

In the study with 1,835 participants, the use of the AdaptivCRT algorithm demonstrated a 31% relative decrease in all-cause mortality compared to standard cardiac resynchronisation therapy (CRT).

AdaptivCRT is designed to personalise therapy by adjusting the implanted CRT device’s pacing capability based on a minute-to-minute assessment of an individual patient’s rhythm.

“It minimised a patient’s odds of a 30-day heart failure re-admission by 59%, increased CRT response rate, decreased unnecessary right ventricular pacing and enhanced outcomes for patients with normal AV conduction.”

It is being further studied in a randomised clinical trial called AdaptResponse for superiority over traditional CRT.

In previous analyses, the algorithm is said to have shown a 46% reduction in atrial fibrillation (AF) episodes, lasting more than 48 hours when compared to patients treated with conventional CRT.

It was also found to minimise a patient’s odds of a 30-day heart failure re-admission by 59%, increase CRT response rate, decrease unnecessary right ventricular pacing and enhance outcomes for patients with normal AV conduction.

Medtronic Cardiac Resynchronization Therapy business vice-president and general manager Kweli Thompson said: “With AdaptivCRT, we are treating heart failure comprehensively, with technology designed to address the individual needs of each patient.

“This analysis shows yet another benefit of AdaptivCRT, and we look forward to results from the randomised, superiority AdaptResponse trial in the coming years.”

The company’s heart failure portfolio comprises CRT devices such as MR-conditional CRT-Ds and CRT-Ps, mechanical circulatory support therapy, diagnostics and expert analysis via Care Management Services.